Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Reindl

Showing results (21-30 of 248) with videos related to

Pageof 25
Sort By:
Central Nervous System Agents in Medicinal Chemistry|March 19, 2010
Multiple sclerosis - established and novel therapeutic approachesRainer Ehling, Thomas Berger, Markus Reindl
Current Medicinal Chemistry|August 21, 2007
Biological markers for multiple sclerosisAndreas Lutterotti, Thomas Berger, Markus Reindl
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|February 2, 2023
The Potential Pathogenicity of Myelin Oligodendrocyte Glycoprotein Antibodies in the Optic PathwayMagdalena Lerch, Angelika Bauer, Markus Reindl
Results and Problems in Cell Differentiation|June 11, 2009
B cells and antibodies in MSMarkus Reindl, Bettina Kuenz, Thomas Berger
Multiple Sclerosis and Related Disorders|March 11, 2018
New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseasesFranziska Di Pauli, Markus Reindl, Thomas Berger
Nature Reviews. Neurology|August 15, 2022
Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex conceptRomana Höftberger, Hans Lassmann, Thomas Berger, et al.
Current Opinion in Neurology|March 2, 2017
Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?Markus Reindl, Sven Jarius, Kevin Rostasy, et al.
Expert Opinion on Medical Diagnostics|March 16, 2013
Diagnostic biomarkers in multiple sclerosisBettina Kuenz, Florian Deisenhammer, Thomas Berger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 11, 2005
In vitro models of multiple system atrophyNadia Stefanova, Markus Reindl, Werner Poewe, et al.
Neurology|March 22, 2019
Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritisHelen Hayward-Koennecke, Markus Reindl, Roland Martin, et al.
Pageof 25

Showing results (21-30 of 248) with videos related to

Sort By:
Pageof 25
Central Nervous System Agents in Medicinal Chemistry|March 19, 2010
Multiple sclerosis - established and novel therapeutic approachesRainer Ehling, Thomas Berger, Markus Reindl
Current Medicinal Chemistry|August 21, 2007
Biological markers for multiple sclerosisAndreas Lutterotti, Thomas Berger, Markus Reindl
Journal of Neuro-Ophthalmology : the Official Journal of the North American Neuro-Ophthalmology Society|February 2, 2023
The Potential Pathogenicity of Myelin Oligodendrocyte Glycoprotein Antibodies in the Optic PathwayMagdalena Lerch, Angelika Bauer, Markus Reindl
Results and Problems in Cell Differentiation|June 11, 2009
B cells and antibodies in MSMarkus Reindl, Bettina Kuenz, Thomas Berger
Multiple Sclerosis and Related Disorders|March 11, 2018
New clinical implications of anti-myelin oligodendrocyte glycoprotein antibodies in children with CNS demyelinating diseasesFranziska Di Pauli, Markus Reindl, Thomas Berger
Nature Reviews. Neurology|August 15, 2022
Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex conceptRomana Höftberger, Hans Lassmann, Thomas Berger, et al.
Current Opinion in Neurology|March 2, 2017
Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?Markus Reindl, Sven Jarius, Kevin Rostasy, et al.
Expert Opinion on Medical Diagnostics|March 16, 2013
Diagnostic biomarkers in multiple sclerosisBettina Kuenz, Florian Deisenhammer, Thomas Berger, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|August 11, 2005
In vitro models of multiple system atrophyNadia Stefanova, Markus Reindl, Werner Poewe, et al.
Neurology|March 22, 2019
Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritisHelen Hayward-Koennecke, Markus Reindl, Roland Martin, et al.
Pageof 25